Who Should Use Penile Traction Therapy | SizeGenetics

Episode Summary

Who should use penile traction therapy — and who shouldn't? This episode breaks down the three evidence-based candidate groups, key contraindications, and what the clinical literature reveals about proper patient selection for penile traction therapy.

Key Findings

• Three candidate groups: Chronic-phase Peyronie's disease, post-prostatectomy rehabilitation, and medically assessed length concerns
• 2023 Meta-Analysis (Almsaoud et al.): 12 studies, 1,000+ patients, 1.9 cm mean length gain and 27% curvature improvement
• Toussi 2021 RCT: Post-prostatectomy patients gained 1.6 cm vs. 0.3 cm in controls, with 93% recommending the therapy
• Adherence threshold: 4–6 hours daily for 3–6 months required for meaningful outcomes
• Safety profile: Adverse events 11.2–14.4%, all mild and temporary, no serious events reported

The Science

Penile traction therapy works through mechanotransduction — the cellular response to sustained mechanical tension that triggers collagen remodeling and tissue expansion. Proper candidacy and adherence are essential to achieve the therapeutic response documented in clinical studies.

About SizeGenetics

FDA-registered Class II medical device, manufactured by Danamedic ApS in Denmark since 1994. Delivers calibrated tension of 900–2,800 grams — the exact therapeutic range used in clinical studies. Over 1 million units sold worldwide.

Resources

• Full Guide: Who Should Use Penile Traction Therapy
• Peyronie's Disease Treatment
• Post-Surgical Rehabilitation
• Safety Profile and Adverse Events
• Treatment Protocol Guide

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any treatment.